Acerta Pharma

18 articles about Acerta Pharma

• CALQUENCE Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients With Chronic Lymphocytic Leukemia

  12/7/2020

  Less than 1% of patients treated with CALQUENCE discontinued treatment due to cardiac adverse events in pooled analysis

• CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma

  12/6/2020

  ACE-LY-004 Phase II trial results substantiate established efficacy and safety profile of CALQUENCE in mantle cell lymphoma

• Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors

  6/22/2020

  Ascentage Pharma, a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and senescence diseases, announced a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca.

• Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma

  1/8/2020

  Agreement enabled by Veracyte acquisition of NanoString diagnostics assets for global expansion

• 

  Veracyte Teams with AstraZeneca's Acerta on Oncology Testing

  1/8/2020

  Under the collaboration deal with Acerta, Veracyte will offer genomic information in support of Acerta’s oncology development program. Financial details were not disclosed.

• Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma

  5/10/2019

  Forty Seven Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence

• New Long-Term Data on CALQUENCE Presented at ASH 2018

  12/3/2018

  26 months median duration of response achieved in relapsed or refractory mantle cell lymphoma at updated two-year analysis

• AstraZeneca Presents Clinical Research Advances for Blood Cancer Patients at 2018 American Society of Hematology Annual Meeting

  11/27/2018

  27 scientific presentations, including long-term data from CALQUENCE in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukemia

• 

  Arix Bioscience Leads $58 Million Series A into VelosBio, Taking 11.2% Stake

  10/1/2018

  VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.
• 

  Dartmouth Health Policy Expert’s Plagiarism Accusations Underline Risk of Data Fraud

  8/21/2018

  H. Gilbert Welch, a health care policy scholar at Dartmouth College, reportedly plagiarized part of the contents in a 2016 New England Journal of Medicine article. The article focused on breast cancer screening and the increased likelihood of tumors being overdiagnosed.
• 

  AstraZeneca Opens New Bay Area R&D Site With 400 Employees

  5/24/2018

  After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area. 

• AstraZeneca's CALQUENCE (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial

  12/11/2017

  The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta and demonstrate the safety profile and efficacy of CALQUENCE in the management of previously-treated mantle cell lymphoma (MCL).

• AstraZeneca’s CALQUENCE (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia Trials

  12/10/2017

  The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta.

• 

  The IDO Battle Gets Ugly

  10/25/2017

  Incyte has been at the forefront of the IDO race with its candidate epacadostat.

• Bay Area Acerta Pharma Falsified Early Data on a Cancer Compound, Now in Clinical Trials

  10/10/2017

• Orphan Drug Designation Status for Acerta Pharma Drug Vindicates AstraZeneca PLC’s $4 Billion Deal

  2/26/2016

• AstraZeneca PLC Takes 55% Stake in Acerta Pharma for $4 Billion with Option to Buy Rest for Another $3 Billion

  12/18/2015

• Pharma Giant AstraZeneca PLC in Advanced Talks to Buy Acerta Pharma for $5 Billion+

  12/15/2015